Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.